EUVIMEDEUVIMED entdecken
Crossref

Treatment Adherence in Patients with Type 2 Diabetes Mellitus: Associations with Clinical and Metabolic Factors

Ahmet Çakır, Hasan Memiş, Ahsen Telli, Esra Tanrıkul, Nesligül Özdemir-Ayduran

Pharmata · 09.07.2026 · 6 (2) · 45-53

DOI: 10.62425/pharmata.1896761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmata, online erschienen am 09.07.2026. Verfasst von Ahmet Çakır und 4 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to assess treatment adherence according to antidiabetic treatment regimens and its associations with medication burden and clinical outcomes in patients with type 2 diabetes mellitus (T2DM).

Methods

This cross-sectional study was conducted between January and April 2024 in the endocrinology department of a tertiary care hospital. Adult patients diagnosed with T2DM for at least one year were included. Sociodemographic data, comorbidities, diabetes-related complications, treatment and lifestyle characteristics, laboratory parameters (HbA1c and C-peptide), and self-reported adherence were recorded. Treatment adherence was assessed using the validated Turkish version of the Treatment Adherence in Type 2 Diabetes Mellitus (TAT2DM) Scale. The study was approved by the XXX Ethics Committee (approval no: 2023/5237).

Results

The study included 198 patients with T2DM. Hypertension was the most common comorbidity, and diabetic peripheral neuropathy was the most frequent complication. The mean TAT2DM score was 85.2 ± 9.2. HbA1c levels were positively correlated with the total number of medications, oral antidiabetic drugs (OADs), and insulin products (p < 0.001), while C-peptide levels were negatively correlated with the number of insulin products (p = 0.010). The total TAT2DM score was negatively associated with the number of insulin products (p = 0.008) and adherence was significantly higher among patients who exercised regularly (p = 0.024). Treatment adherence and HbA1c levels differed significantly across antidiabetic regimens, with higher adherence and HbA1c observed in patients receiving combined insulin and OAD therapy (p

Zitieren

APA

Çakır, A., Memiş, H., Telli, A., Tanrıkul, E., & Özdemir-Ayduran, N. (2026). Treatment Adherence in Patients with Type 2 Diabetes Mellitus: Associations with Clinical and Metabolic Factors. Pharmata, 6(2), 45-53. https://doi.org/10.62425/pharmata.1896761

Vancouver

Çakır A, Memiş H, Telli A, Tanrıkul E, Özdemir-Ayduran N. Treatment Adherence in Patients with Type 2 Diabetes Mellitus: Associations with Clinical and Metabolic Factors. Pharmata. 2026;6(2):45-53. doi:10.62425/pharmata.1896761

BibTeX
@article{akr2026,
  author = {Çakır, Ahmet and Memiş, Hasan and Telli, Ahsen and Tanrıkul, Esra and Özdemir-Ayduran, Nesligül},
  title = {Treatment Adherence in Patients with Type 2 Diabetes Mellitus: Associations with Clinical and Metabolic Factors},
  journal = {Pharmata},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {45--53},
  doi = {10.62425/pharmata.1896761}
}
Kostenlos starten →